Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Canakinumab

Brand: 
NICE TA: 281 (terminated)
Indication: Gouty arthritis (NICE 281 - terminated appraisal)
Disease category: Musculoskeletal and joint disease
Commissioning responsibility: CCG
PbR excluded: Yes

Background

The NICE appraisal was suspended as the manufacturer had not engaged with the NICE review process.

Recommendation

LMMG recommendation: Black
Click here to find the definitions for the colour classifications

Reason for decision:  Uncertaintly around the risk to benefit ratio with safety concerns around cardiovascular and renal function, serious infections and neutropenia.

Supporting documents:

NICE TA281 - Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal) 

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Black

Black

Black

Black

Black

Black